Improving NK Cell-based Cancer Immunotherapy via mRNA Electroporation
Natural Killer (NK) cells are cytotoxic lymphocytes that can kill tumor-transformed and infected cells. In contrast to T cells, genetic engineering of NK cells using viral vectors has only recently started to show sufficient efficacy. Currently, viral approaches are associated with high costs and excessive regulatory work-load if used in the clinic. Genetic engineering of NK cells via mRNA electroporation has instead shown to be more efficient than viral transduction and is likely associated with less regulatory work-load for clinical realization. This webinar will focus on the current developments of mRNA electroporation of NK cells, including its efficacy and impact on cellular viability, proliferation, receptor expression and baseline cytotoxicity. Examples will be discussed for how mRNA electroporation can be used to modulate multiple properties of NK cells and thereby potentially further improve the outcome of cancer patients treated with NK cell-based immunotherapies in the future.
Presenter: Mattias Carlsten, MD PhD
Assistant Professor, Group Leader